This summary was created by AI, based on 2 opinions in the last 12 months.
Carl Zeiss Meditec, symbol AFX-O, is currently navigating a recovery phase after experiencing significant fluctuations in its share price, which peaked earlier this year at 150 Euros before facing downturns due to weakened sales in crucial markets such as China and North America. Expert reviews indicate that the company, known for producing surgical microscopes and laser surgery equipment, has solid fundamentals, including ample cash reserves and an asset-light business model. The recent predictions highlight an optimistic price target of 83.58 Euros, driven by expectations of an impending decline in US interest rates, which could further bolster its performance. As signs of recovery in Chinese sales emerge, experts note this could positively influence the stock's trajectory, making it a potential buy for investors looking for turnaround opportunities.
They make lenses for microscopes used by surgeons, and mirrors for ASML. Share are down from 150 Euros due to slowing sales in China and North America. They also make laser surgery equipment. But it's an asset-lite company with tons of cash. It trades at 13x PE 2026. If interest rate decline, they will benefit.
Carl Zeiss Meditec is a OTC stock, trading under the symbol AFX-O on the (). It is usually referred to as or AFX-O
In the last year, 1 stock analyst published opinions about AFX-O. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Carl Zeiss Meditec.
Carl Zeiss Meditec was recommended as a Top Pick by on . Read the latest stock experts ratings for Carl Zeiss Meditec.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
In the last year, there was no coverage of Carl Zeiss Meditec published on Stockchase.
On , Carl Zeiss Meditec (AFX-O) stock closed at a price of $.
All his past picks on this date were small-caps and chosen, based on him expecting US interest rates to fall. All were turnaround plays. He used dollar-cost averaging. AFX peaked in March 2024, fell in July and since up slightly. Is turning around now. Fell because Chinese sales weakened, but that is recovering now. Is buying more.